131 related articles for article (PubMed ID: 1396349)
1. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion.
Demura R; Naruse M; Isawa M; Onoda N; Naruse K; Yamakado M; Demura H
Endocrinol Jpn; 1992 Apr; 39(2):169-76. PubMed ID: 1396349
[TBL] [Abstract][Full Text] [Related]
2. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic regulation of aldosterone secretion: its pathophysiologic significance in subsets of primary aldosteronism.
Naruse M; Naruse K; Yoshimoto T; Tanaka M; Tanabe A; Imaki T; Shibasaki T; Demura R; Demura H
Hypertens Res; 1995 Jun; 18 Suppl 1():S59-64. PubMed ID: 8529076
[TBL] [Abstract][Full Text] [Related]
4. [Dopaminergic regulation of the hypothalamo-hypophyseal system in patients with hypophyseal adenomas].
Balabolkin MI; Gerasimov GA; Snigireva RIa; Pisarskaia IV; Liubimov AV
Probl Endokrinol (Mosk); 1989; 35(5):3-6. PubMed ID: 2587520
[TBL] [Abstract][Full Text] [Related]
5. Plasma aldosterone response to metoclopramide is unmodified by hyperprolactinemia.
Serri O
Horm Res; 1987; 27(1):36-41. PubMed ID: 3623428
[TBL] [Abstract][Full Text] [Related]
6. [The effect of dopaminergic antagonists on plasma aldosterone in normal subjects and patients with hypopituitarism].
Shikuma R; Yoshimura M; Takashina R; Yamazaki H; Kambara S; Ijichi H
Nihon Naibunpi Gakkai Zasshi; 1984 Sep; 60(9):1041-5. PubMed ID: 6394371
[TBL] [Abstract][Full Text] [Related]
7. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
9. Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: possible therapeutic approach.
Sowers J; Catania R; Paris J; Tuck M
J Clin Endocrinol Metab; 1982 Mar; 54(3):510-6. PubMed ID: 7035482
[TBL] [Abstract][Full Text] [Related]
10. Effects of metoclopramide and bromocriptine on the renin-angiotensin-aldosterone system in man. Dopaminergic control of aldosterone.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1979 Apr; 63(4):727-35. PubMed ID: 438333
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
[TBL] [Abstract][Full Text] [Related]
12. Altered dopaminergic modulation of prolactin and aldosterone secretion in pseudohypoparathyroidism.
Sowers JR; Brickman AS; Asp N; Tuck ML; Jasberg K; Magnone S
J Clin Endocrinol Metab; 1981 May; 52(5):914-8. PubMed ID: 7014587
[TBL] [Abstract][Full Text] [Related]
13. Effect of metergoline on the aldosterone-stimulating properties of metoclopramide.
Opocher G; Murgia A; Boscaro M; D'Agostino D; Fallo F; Mantero F
J Steroid Biochem; 1983 Jul; 19(1B):531-6. PubMed ID: 6350721
[TBL] [Abstract][Full Text] [Related]
14. Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
Jungmann E; Schwedes U; Althoff PH; Rosak C; Schöffling K
Horm Metab Res; 1986 Oct; 18(10):704-5. PubMed ID: 3781476
[TBL] [Abstract][Full Text] [Related]
15. Evidence for dopamine-related and TRH-related pituitary TSH and PRL pools in patients with prolactinoma.
Hanew K; Utsumi A; Sugawara A; Shimizu Y; Yoshinaga K
Acta Endocrinol (Copenh); 1991 May; 124(5):545-52. PubMed ID: 1903012
[TBL] [Abstract][Full Text] [Related]
16. Zona fasciculata-like cells determine the response of plasma aldosterone to metoclopramide and aldosterone synthase messenger ribonucleic acid level in aldosterone-producing adenoma.
Wu KD; Chen YM; Chu JS; Hung KY; Hsieh TS; Hsieh BS
J Clin Endocrinol Metab; 1995 Mar; 80(3):783-9. PubMed ID: 7883831
[TBL] [Abstract][Full Text] [Related]
17. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
18. Prolactin secretion in the empty sella syndrome, in prolactinomas and in acromegaly.
Brismar K
Acta Med Scand; 1981; 209(5):397-405. PubMed ID: 6787839
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism.
Witzgall H; von Werder K; Weber PC
J Steroid Biochem; 1983 Nov; 19(5):1671-6. PubMed ID: 6645503
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic modulation of aldosterone secretions on changes of sodium intake in aldosterone-producing adenoma.
Wu KD; Chen YM; Chu TS; Chueh SC; Tsai GC; Tseng YZ; Hsieh BS
Am J Hypertens; 2002 Jul; 15(7 Pt 1):609-14. PubMed ID: 12118908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
